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CABG = coronary artery bypass grafting; GP = glycoprotein; MI = myocardial infarction; PCI = percutaneous coronary intervention; TVR = target
vessel revascularization.
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= Do Tirofiban and ReoPro Give Similar Efficacy Trial.
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Large, randomized trials of multivessel balloon angioplasty
versus coronary artery bypass grafting (CABG) in aggregate
show no difference in long-term mortality in patients
randomized to either approach initially [1,2]. There is,
however, an increased need for subsequent percutaneous or
surgical target vessel revascularization (TVR) in patients who
initially undergo balloon angioplasty. Additionally, in patients
with diabetes mellitus, there appears to be a mortality benefit
favoring an initial surgical approach for multivessel disease.
Compared with balloon angioplasty, stenting unequivocally
reduces the need for TVR across a variety of lesion types
[3–7]. However, there has never been evidence from
randomized trials that stents decrease mortality, compared
with balloon angioplasty. Indeed, existing data suggest that
stents may increase mortality, in both acute myocardial
infarction (MI) [8] and chronic stable angina [9]. The
observed increase in mortality is likely to be related to the
fact that stenting leads to more embolization than balloon
angioplasty. This is manifest by increased periprocedural MI
[10], through what has been termed a ‘cheese grater’ effect
due to embolization of the plaque by the stent [11]. By
contradistinction, CABG has been shown to decrease
mortality in certain patient subgroups [12]. Data are
particularly strong for patients with multivessel disease, left
ventricular dysfunction, and left main coronary stenosis.
However, compared with percutaneous coronary intervention
(PCI), CABG carries a greater risk of death, MI, and stroke,
as well as a risk of more subtle deficits in cognitive function
[13]. For patients who have coronary anatomy suitable for
either multivessel stenting or CABG, the question thus arises
as to which is the better approach.
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Abstract
The Arterial Revascularization Therapy Study (ARTS) and the Stent or Surgery (SoS) trial each
randomized patients with multivessel disease to either stenting or bypass surgery. The ARTS showed
no difference in mortality between the two strategies, other than in diabetic patients, who fared better
with surgery. The SoS trial demonstrated increased mortality in the stent arm, a difference that was not
attributable to diabetes. Both trials found that the rates of repeat revascularization were lower with
surgery, although the rate with stenting was much lower than had been seen in previous trials of
angioplasty. Use of antiplatelet therapy such as intravenous glycoprotein IIb/IIIa inhibitors, especially
with their pronounced effects in diabetics and in those with multivessel disease, could potentially
equalize the playing field or perhaps even tip the balance in favor of percutaneous intervention.
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Stenting versus CABG for multivessel disease
The evidence
The ARTS and the SoS trial attempted to determine whether
stenting would shift the balance in favor of multivessel PCI
instead of CABG as the better approach [14].
The ARTS found that patients randomized to either stenting
or CABG had similar rates of mortality after 1 year. TVR rates
were lower with stenting than they had been in previous trials
of balloon angioplasty; however, the CABG arm of the trial
still had a significantly lower rate of TVR. The diabetic cohort
did have a higher mortality in the stenting arm than in the
CABG arm of the trial.
The SoS study found a lower mortality at 1 year in those
undergoing CABG instead of PCI (0.8% versus 2.5%) [15].
As the prevalence of diabetes was quite low in the SoS trial,
the increased mortality seen in the PCI patients cannot be
attributed to this factor. While the results of SoS have in part
been explained by some interventional cardiologists as
‘surprisingly low surgical mortality’ in the patients randomized
to CABG, that level of mortality is not unreasonable with
contemporary surgical technique. At the Cleveland Clinic, in
a high-risk population, the perioperative mortality rate from
CABG was 0.8% for the year 2000. There were a larger
number of cancer deaths in the PCI arm than in the CABG
arm in the SoS trial, and ‘play of chance’ is the most likely
explanation for this finding. However, to dismiss outright the
mortality difference observed in this randomized trial is
scientifically unjustified.
The winner
Is CABG the treatment of choice for multivessel disease,
particularly in the diabetic patient? Is the battle over? Well,
not in our opinion. In both these trials, the fight was an unfair
one from the start.
The PCI arms of both trials were sent to war without their
armor. In contemporary PCI, the role of concomitant
glycoprotein (GP) IIb/IIIa inhibition is firmly established. The
Evaluation of IIb/IIIa Platelet Inhibitor for Stenting (EPISTENT)
study demonstrated reduced mortality in patients receiving
stents who were randomized to abciximab instead of placebo
[16]. This mortality benefit of GP IIb/IIIa blockade is amplified in
diabetic patients. In fact, in a pooled analysis of the abciximab
in PCI trials, diabetic patients who were randomized to
abciximab demonstrated mortality rates similar to that of non-
diabetic patients receiving placebo [17]. Thus, abciximab
administration essentially converted the risk of death for the
diabetic to that of a non-diabetic. This mortality benefit is
particularly marked in the subset of diabetics with multivessel
disease [18]. If these findings are extrapolated to the ARTS
diabetic substudy results, then the gap in mortality rates
between PCI and CABG might vanish. Additionally, the
EPISTENT trial showed that abciximab reduced clinical and
angiographic restenosis in diabetic patients [19]. Importantly,
restenosis may be linked to subsequent mortality in diabetics
[20], and any benefit of abciximab in reducing TVR may
consequently be linked to a survival advantage. GP IIb/IIIa
blockade could thus have changed the results of the ARTS
and the SoS trial dramatically both in terms of TVR and
mortality, although this concept should be tested prospectively.
The Do Tirofiban and ReoPro Give Similar Efficacy Trial
(TARGET) found that abciximab was superior to tirofiban in
reducing death, MI, or TVR after 30 days [21]. Thus, while all
three commercially available intravenous GP IIb/IIIa inhibitors
reduce periprocedural MI, it may be that abciximab in
particular has an additional effect on TVR in diabetics with
stents. However, further analysis of the TARGET study
6-month results for diabetics will be necessary to determine
whether abciximab indeed had a specific effect.
Furthermore, the beneficial impact of long-term clopidogrel
on patients with stents is currently being evaluated in the
Clopidogrel for Reduction of Events During Observation trial.
Prolonged dual antiplatelet therapy with aspirin plus the
thienopyridine, clopidogrel, could further decrease both TVR
(as had been shown with ticlopidine) and recurrent ischemic
events [22,23]. Additionally, such a pharmacological
approach may be applicable and beneficial after CABG [24].
Statin therapy and appropriate control of diabetes would be
expected to improve outcome in PCI patients but, again,
some degree of risk reduction would also be expected in the
CABG patients. Drug-coated stents, currently being tested in
clinical trials, could ultimately reduce restenosis rates to an
unprecedented low level [25]. Off-pump surgery may
diminish the cognitive decline noted with CABG.
Conclusion
Both PCI and CABG (as well as medical therapy) are
improving. At present, a patient with multivessel disease may
be considered for either PCI or CABG. When the disease is
more extensive, when left ventricular dysfunction is more
severe, or in the presence of diabetes, CABG may be the
preferred mode of revascularization. However, PCI may be
performed when there are more focal stenoses, although
concomitant GP IIb/IIIa inhibition is essential. Given the clinical
benefits and proven cost-effectiveness of GP IIb/IIIa inhibition
[16], there is no longer justification for PCI without GP IIb/IIIa
blockade, particularly in those patients with heightened risk
features, such as multivessel disease or diabetes.
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